{"nctId":"NCT02158572","briefTitle":"Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System","startDateStruct":{"date":"2014-08","type":"ACTUAL"},"conditions":["Healthy"],"count":2032,"armGroups":[{"label":"AG200-15","type":"EXPERIMENTAL","interventionNames":["Drug: AG200-15"]}],"interventions":[{"name":"AG200-15","otherNames":["Transdermal contraceptive delivery system"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, sexually active woman at risk for pregnancy seeking to use hormonal contraception for at least 1 year\n* Ability to demonstrate willingness to participate and adhere to study protocol\n\nExclusion Criteria:\n\n* Known or suspected pregnancy\n* Lactating women\n* Anticipates use of condoms or any other form of back-up contraception during the study\n* History of dermal sensitivity to medicated patches (nicotine) or to bandages, surgical tape, etc.\n* Has a contraindication to combined estrogen-progestin contraceptive use\n* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)\n* Smoker who is 35 years old or over","healthyVolunteers":true,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.","description":"The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI < 25 kg/m2, ITT Dataset","description":"Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI \\< 25 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI ≥ 25 and < 30 kg/m2, ITT Dataset","description":"Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI ≥ 25 and \\< 30 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Self-reported Skin Irritation at Application Site","description":"Self-reported skin irritation at application site was assessed using the following scoring method:\n\n0: None\n\n1. Mild\n2. Moderate\n3. Severe","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"1.020"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Self-reported Skin Itching at Application Site","description":"Self-reported skin itching at application site was assessed using the following scoring method:\n\n0: None\n\n1. Mild\n2. Moderate\n3. Severe","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.951"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Self-reported Patch Adhesion","description":"Patch adhesion was reported using the following 5-point scoring method:\n\n0: ≥ 90% adhered (none to minimal lift)\n\n1. ≥ 75% adhered but \\< 90% (some edges showing lift)\n2. ≥ 50% adhered but \\< 75% (at least half of system lifts off)\n3. \\< 50% (more than half of the patch lifts off, but the patch remains attached)\n4. Patch completely detached.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":"1.518"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cycle Control","description":"Number of episodes of breakthrough bleeding (BTB) and/or breakthrough spotting (BTS) per cycle.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.391"}]}]}]},{"type":"SECONDARY","title":"Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI ≥ 30 kg/m2, ITT Dataset","description":"Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI ≥ 30 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":2031},"commonTop":["Nasopharyngitis","Upper respiratory infection","Nausea","Headache","Urinary tract infection"]}}}